These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 15245690)

  • 61. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.
    Burchert A; Müller MC; Kostrewa P; Erben P; Bostel T; Liebler S; Hehlmann R; Neubauer A; Hochhaus A
    J Clin Oncol; 2010 Mar; 28(8):1429-35. PubMed ID: 20142590
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 63. First-Line management of CML: a state of the art review.
    Hochhaus A
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S1-S10. PubMed ID: 18397676
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; O'Brien S; Jones D; Giles F; Garcia-Manero G; Faderl S; Ravandi F; Rios MB; Shan J; Cortes J
    Blood; 2006 Sep; 108(6):1835-40. PubMed ID: 16709931
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Johnson JR; Bross P; Cohen M; Rothmann M; Chen G; Zajicek A; Gobburu J; Rahman A; Staten A; Pazdur R
    Clin Cancer Res; 2003 Jun; 9(6):1972-9. PubMed ID: 12796358
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation.
    Cervantes F; Hernández-Boluda JC; Odriozola J; Camós M; Villalón L; Martínez-Climent JA; del Campo R; García-Conde J; Montserrat E
    Br J Haematol; 2003 Feb; 120(3):500-4. PubMed ID: 12580969
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
    Breitscheidel L
    J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy.
    Weisser M; Schleuning M; Haferlach C; Schwerdtfeger R; Kolb HJ
    Leuk Lymphoma; 2007 Feb; 48(2):295-301. PubMed ID: 17325889
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
    Simonsson B; Gedde-Dahl T; Markevärn B; Remes K; Stentoft J; Almqvist A; Björeman M; Flogegård M; Koskenvesa P; Lindblom A; Malm C; Mustjoki S; Myhr-Eriksson K; Ohm L; Räsänen A; Sinisalo M; Själander A; Strömberg U; Bjerrum OW; Ehrencrona H; Gruber F; Kairisto V; Olsson K; Sandin F; Nagler A; Nielsen JL; Hjorth-Hansen H; Porkka K;
    Blood; 2011 Sep; 118(12):3228-35. PubMed ID: 21685374
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
    Hochhaus A; Druker B; Sawyers C; Guilhot F; Schiffer CA; Cortes J; Niederwieser DW; Gambacorti-Passerini C; Stone RM; Goldman J; Fischer T; O'Brien SG; Reiffers JJ; Mone M; Krahnke T; Talpaz M; Kantarjian HM
    Blood; 2008 Feb; 111(3):1039-43. PubMed ID: 17932248
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
    Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Drug therapy of chronic myeloid leukemia].
    Hochhaus A; Berger U; Reiter A; Lahaye T; Kreil S; Hehlmann R
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():7-15. PubMed ID: 11831070
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
    Kantarjian HM; O'Brien S; Cortes JE; Smith TL; Rios MB; Shan J; Yang Y; Giles FJ; Thomas DA; Faderl S; Garcia-Manero G; Jeha S; Wierda W; Issa JP; Kornblau SM; Keating M; Resta D; Capdeville R; Talpaz M
    Clin Cancer Res; 2002 Jul; 8(7):2167-76. PubMed ID: 12114417
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006.
    Wang AH; Wang YY; Yao Y; Xu ZZ; Zhou L; Wang L; Zhang L; Chen Y; Shen ZX; Hu J; Li JM
    J Exp Clin Cancer Res; 2010 Mar; 29(1):20. PubMed ID: 20199658
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Quality of life on imatinib.
    Hahn EA; Glendenning GA
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):31-6. PubMed ID: 12783373
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
    Ghatnekar O; Hjalte F; Taylor M
    Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Successful use of National Cancer Registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia.
    Shepherd P; Dhanapala C; Maguire C; White J; Drummond M; Holyoake T; Johnson PR
    Scott Med J; 2008 Aug; 53(3):8-12. PubMed ID: 18780518
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000.
    Harrison SJ; Johnson PR; Holyoake TL
    Scott Med J; 2004 Aug; 49(3):87-90. PubMed ID: 15462221
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.
    Li N; Zheng B; Cai HF; Yang J; Luo XF; Weng LZ; Zhan FM; Liu MB
    Clin Drug Investig; 2018 Jan; 38(1):79-86. PubMed ID: 29027641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.